Summit Therapeutics shared on LinkedIn:
“AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics.
Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price.
Summit Also Enters into Clinical Trial Collaboration with AstraZeneca to Evaluate Ivonescimab in Combination with Sonesitatug Vedotin in Multiple Gastrointestinal Cancers.
Summit and AstraZeneca Plan to Enter into a Clinical Trial Collaboration Combining Ivonescimab with Multiple AstraZeneca ADCs and Other Cancer Medicines
Full Press Release Here: AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).”
Other articles about Summit Therapeutics on OncoDaily.